Extracellular Traps: A Novel Therapeutic Target for Severe Asthma

References

• Dharmage SC, Perret JL, Custovic A. Epidemiology of asthma in children and adults. Front Pediatr. 2019;7:246. doi:10.3389/fped.2019.00246
   PubMed Web of Science ®Google Scholar
• Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group Phase 3 trials. Lancet. 2019;394(10209):1638–1650. doi:10.1016/S0140-6736(19)31881-1
   PubMed Web of Science ®Google Scholar
• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013
   PubMed Web of Science ®Google Scholar
• Poddighe D, Brambilla I, Licari A, Marseglia GL. Omalizumab in the therapy of pediatric asthma. Recent Pat Inflamm Allergy Drug Discov. 2018;12(2):103–109. doi:10.2174/1872213X12666180430161351
   PubMed Web of Science ®Google Scholar
• Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18(5):716–725. doi:10.1038/nm.2678
   PubMed Web of Science ®Google Scholar
• Robinson D, Humbert M, Buhl R, et al. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017;47(2):161–175. doi:10.1111/cea.12880
   PubMed Web of Science ®Google Scholar
• Lee Y, Quoc QL, Park HS. Biomarkers for severe asthma: lessons from longitudinal cohort studies. Allergy Asthma Immunol Res. 2021;13(3):375–389. doi:10.4168/aair.2021.13.3.375
   PubMed Web of Science ®Google Scholar
• McGregor MC, Krings JG, Nair P, Castro M. Role of biologics in asthma. Am J Respir Crit Care Med. 2019;199(4):433–445. doi:10.1164/rccm.201810-1944CI
   PubMed Web of Science ®Google Scholar
• Granger V, Taille C, Roach D, et al. Circulating neutrophil and eosinophil extracellular traps are markers of severe asthma. Allergy. 2020;75(3):699–702. doi:10.1111/all.14059
   PubMed Web of Science ®Google Scholar
• Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1):1900588. doi:10.1183/13993003.00588-2019
   PubMed Web of Science ®Google Scholar
• Reddel HK, Bacharier LB, Bateman ED, et al. Global initiative for asthma strategy 2021: executive summary and rationale for key changes. Eur Respir J. 2022;59(1):2102730. doi:10.1183/13993003.02730-2021
   PubMed Web of Science ®Google Scholar
• Bush A, Zar HJ. WHO universal definition of severe asthma. Curr Opin Allergy Clin Immunol. 2011;11(2):115–121. doi:10.1097/ACI.0b013e32834487ae
   PubMed Web of Science ®Google Scholar
• Ricciardolo FL, Bertolini F, Carriero V, Sprio AE. Asthma phenotypes and endotypes. Minerva Med. 2021;112(5):547–563. doi:10.23736/S0026-4806.21.07498-X
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2–driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180(5):388–395. doi:10.1164/rccm.200903-0392OC
   PubMed Web of Science ®Google Scholar
• Gibson PG, Saltos N, Borgas T. Airway mast cells and eosinophils correlate with clinical severity and airway hyperresponsiveness in corticosteroid-treated asthma. J Allergy Clin Immunol. 2000;105(4):752–759. doi:10.1067/mai.2000.105319
   PubMed Web of Science ®Google Scholar
• Poddighe D, Mathias CB, Brambilla I, Marseglia GL, Oettgen HC. Importance of basophils in eosinophilic asthma: the murine counterpart. J Biol Regul Homeost Agents. 2018;32(2):335339.
   Web of Science ®Google Scholar
• Sim S, Choi Y, Park HS. Potential metabolic biomarkers in adult asthmatics. Metabolites. 2021;11(7):430. doi:10.3390/metabo11070430
   PubMed Web of Science ®Google Scholar
• Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol. 2004;113(1):101–108. doi:10.1016/j.jaci.2003.10.041
   PubMed Web of Science ®Google Scholar
• Moore WC, Peters SP. Severe asthma: an overview. J Allergy Clin Immunol. 2006;117(3):487–494; quiz 495. doi:10.1016/j.jaci.2006.01.033
   Web of Science ®Google Scholar
• Lee JH, Haselkorn T, Borish L, Rasouliyan L, Chipps BE, Wenzel SE. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest. 2007;132(6):1882–1889. doi:10.1378/chest.07-0713
   PubMed Web of Science ®Google Scholar
• Lee HY, Ye YM, Kim SH, et al. Identification of phenotypic clusters of nonsteroidal antiinflammatory drugs exacerbated respiratory disease. Allergy. 2017;72(4):616–626. doi:10.1111/all.13075
   PubMed Web of Science ®Google Scholar
• Woo SD, Luu QQ, Park HS. NSAID-Exacerbated Respiratory Disease (NERD): from pathogenesis to improved care. Front Pharmacol. 2020;11:1147. doi:10.3389/fphar.2020.01147
   PubMed Web of Science ®Google Scholar
• Kuruvilla ME, Lee F, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2019;56(2):219–233. doi:10.1007/s12016-018-8712-1
   PubMed Web of Science ®Google Scholar
• Israel E, Reddel HK, Drazen JM. Severe and difficult-to-treat asthma in adults. N Engl J Med. 2017;377(10):965–976. doi:10.1056/NEJMra1608969
   PubMed Web of Science ®Google Scholar
• Loza MJ, Djukanovic R, Chung KF, et al. Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study. Respir Res. 2016;17(1):165. doi:10.1186/s12931-016-0482-9
   PubMed Web of Science ®Google Scholar
• Choi Y, Lee Y, Park HS. Neutrophil activation in occupational asthma. Curr Opin Allergy Clin Immunol. 2019;19(2):81–85. doi:10.1097/ACI.0000000000000507
   PubMed Web of Science ®Google Scholar
• Hastie AT, Mauger DT, Denlinger LC, et al. Mixed sputum granulocyte longitudinal impact on lung function in the severe asthma research program. Am J Respir Crit Care Med. 2021;203(7):882–892. doi:10.1164/rccm.202009-3713OC
   PubMed Web of Science ®Google Scholar
• Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: moving toward precision medicine. J Allergy Clin Immunol. 2019;144(1):1–12. doi:10.1016/j.jaci.2019.05.031
   PubMed Web of Science ®Google Scholar
• Beuther DA, Sutherland ER. Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies. Am J Respir Crit Care Med. 2007;175(7):661–666. doi:10.1164/rccm.200611-1717OC
   PubMed Web of Science ®Google Scholar
• Gibson PG, Reddel H, McDonald VM, et al. Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry. Intern Med J. 2016;46(9):1054–1062. doi:10.1111/imj.13166
   PubMed Web of Science ®Google Scholar
• Gibeon D, Batuwita K, Osmond M, et al. Obesity-associated severe asthma represents a distinct clinical phenotype: analysis of the British Thoracic Society Difficult Asthma Registry Patient cohort according to BMI. Chest. 2013;143(2):406–414. doi:10.1378/chest.12-0872
   PubMed Web of Science ®Google Scholar
• Choi Y, Kim M, Kim SJ, Yoo HJ, Kim SH, Park HS. Metabolic shift favoring C18:0 ceramide accumulation in obese asthma. Allergy. 2020;75(11):2858–2866. doi:10.1111/all.14366
   PubMed Web of Science ®Google Scholar
• Peters U, Dixon AE, Forno E. Obesity and asthma. J Allergy Clin Immunol. 2018;141(4):1169–1179. doi:10.1016/j.jaci.2018.02.004
   PubMed Web of Science ®Google Scholar
• Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178(3):218–224. doi:10.1164/rccm.200711-1754OC
   PubMed Web of Science ®Google Scholar
• Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181(4):315–323. doi:10.1164/rccm.200906-0896OC
   PubMed Web of Science ®Google Scholar
• Tashiro H, Takahashi K, Sadamatsu H, et al. Biomarkers for overweight in adult-onset asthma. J Asthma Allergy. 2020;13:409–414. doi:10.2147/JAA.S276371
   PubMed Web of Science ®Google Scholar
• Mukherjee M, Lacy P, Ueki S. Eosinophil extracellular traps and inflammatory pathologies—untangling the web. Front Immunol. 2018;9:2763. doi:10.3389/fimmu.2018.02763
   PubMed Web of Science ®Google Scholar
• Choi Y, Sim S, Park HS. Distinct functions of eosinophils in severe asthma with type 2 phenotype: clinical implications. Korean J Intern Med. 2020;35(4):823–833. doi:10.3904/kjim.2020.022
   PubMed Web of Science ®Google Scholar
• Yousefi S, Gold JA, Andina N, et al. Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat Med. 2008;14(9):949–953.
   PubMed Web of Science ®Google Scholar
• Morshed M, Yousefi S, Stöckle C, Simon HU, Simon D. Thymic stromal lymphopoietin stimulates the formation of eosinophil extracellular traps. Allergy. 2012;67(9):1127–1137. doi:10.1038/nm.1855
   PubMed Web of Science ®Google Scholar
• Kim HJ, Sim MS, Lee DH, et al. Lysophosphatidylserine induces eosinophil extracellular trap formation and degranulation: implications in severe asthma. Allergy. 2020;75(12):3159–3170. doi:10.1111/all.14450
   PubMed Web of Science ®Google Scholar
• Ueki S, Tokunaga T, Melo RCN, et al. Charcot-Leyden crystal formation is closely associated with eosinophil extracellular trap cell death. Blood. 2018;132(20):2183–2187. doi:10.1182/blood-2018-04-842260
   PubMed Web of Science ®Google Scholar
• Diny NL, Rose NR, Cihakova D. Eosinophils in autoimmune diseases. Front Immunol. 2017;8:484. doi:10.3389/fimmu.2017.00484
   PubMed Web of Science ®Google Scholar
• Choi Y, Le Pham D, Lee DH, Lee SH, Kim SH, Park HS. Biological function of eosinophil extracellular traps in patients with severe eosinophilic asthma. Exp Mol Med. 2018;50(8):1–8. doi:10.1038/s12276-018-0167-1
   Web of Science ®Google Scholar
• Choi Y, Kim YM, Lee HR, et al. Eosinophil extracellular traps activate type 2 innate lymphoid cells through stimulating airway epithelium in severe asthma. Allergy. 2020;75(1):95–103. doi:10.1111/all.13997
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532–1535. doi:10.1126/science.1092385
   PubMed Web of Science ®Google Scholar
• Abdo M, Uddin M, Goldmann T, et al. Raised sputum extracellular DNA confers lung function impairment and poor symptom control in an exacerbation-susceptible phenotype of neutrophilic asthma. Respir Res. 2021;22(1):167. doi:10.1186/s12931-021-01759-z
   PubMed Web of Science ®Google Scholar
• Choi Y, Pham LD, Lee DH, et al. Neutrophil extracellular DNA traps induce autoantigen production by airway epithelial cells. Mediators Inflamm. 2017;2017:5675029. doi:10.1155/2017/5675029
   PubMed Web of Science ®Google Scholar
• Klopf J, Brostjan C, Eilenberg W, Neumayer C. Neutrophil extracellular traps and their implications in cardiovascular and inflammatory disease. Int J Mol Sci. 2021;22:(2):559. doi:10.3390/ijms22020559
   Web of Science ®Google Scholar
• Kimball AS, Obi AT, Diaz JA, Henke PK. The emerging role of NETs in venous thrombosis and immunothrombosis. Front Immunol. 2016;7:236. doi:10.3389/fimmu.2016.00236
   PubMed Web of Science ®Google Scholar
• D’Abbondanza M, Martorelli EE, Ricci MA, et al. Increased plasmatic NETs by-products in patients in severe obesity. Sci Rep. 2019;9(1):14678. doi:10.1038/s41598-019-51220-x
   PubMed Web of Science ®Google Scholar
• Camicia G, Pozner R, de Larranaga G. Neutrophil extracellular traps in sepsis. Shock. 2014;42(4):286–294. doi:10.1097/SHK.0000000000000221
   PubMed Web of Science ®Google Scholar
• Barnado A, Crofford LJ, Oates JC. At the bedside: neutrophil extracellular traps (NETs) as targets for biomarkers and therapies in autoimmune diseases. J Leukoc Biol. 2016;99(2):265–278. doi:10.1189/jlb.5BT0615-234R
   PubMed Web of Science ®Google Scholar
• Mutua V, Gershwin LJ. A review of neutrophil extracellular traps (NETs) in disease: potential Anti-NETs therapeutics. Clin Rev Allergy Immunol. 2021;61(2):194–211. doi:10.1007/s12016-020-08804-7
   PubMed Web of Science ®Google Scholar
• Pham DL, Ban GY, Kim SH, et al. Neutrophil autophagy and extracellular DNA traps contribute to airway inflammation in severe asthma. Clin Exp Allergy. 2017;47(1):57–70. doi:10.1111/cea.12859
   PubMed Web of Science ®Google Scholar
• Lachowicz Scroggins ME, Dunican EM, Charbit AR, et al. Extracellular DNA, neutrophil extracellular traps, and inflammasome activation in severe asthma. Am J Respir Crit Care Med. 2019;199(9):1076–1085. doi:10.1164/rccm.201810-1869OC
   PubMed Web of Science ®Google Scholar
• Quoc QL, Choi Y, Thi Bich TC, Yang EM, Shin YS, Park HS. S100A9 in adult asthmatic patients: a biomarker for neutrophilic asthma. Exp Mol Med. 2021;53(7):1170–1179. doi:10.1038/s12276-021-00652-5
   PubMed Web of Science ®Google Scholar
• Bich TCT, Quoc QL, Choi Y, et al. Serum Amyloid A1: a biomarker for neutrophilic airway inflammation in adult asthmatic patients. Allergy Asthma Immunol Res. 2022;14(1):40–58. doi:10.4168/aair.2022.14.1.40
   PubMed Web of Science ®Google Scholar
• Kang N, Song WJ. Discovering biomarkers of neutrophilic asthma: a clinician’s perspective. Allergy Asthma Immunol Res. 2022;14(1):1–4. doi:10.4168/aair.2022.14.1.1
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi:10.1016/S0140-6736(12)60988-X
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa1403290
   PubMed Web of Science ®Google Scholar
• Krings JG, McGregor MC, Bacharier LB, Castro M. Biologics for severe asthma: treatment-specific effects are important in choosing a specific agent. J Allergy Clin Immunol Pract. 2019;7(5):1379–1392. doi:10.1016/j.jaip.2019.03.008
   PubMed Web of Science ®Google Scholar
• Nabe T. Steroid-resistant asthma and neutrophils. Biol Pharm Bull. 2020;43(1):31–35. doi:10.1248/bpb.b19-00095
   PubMed Web of Science ®Google Scholar
• Chen X, Li Y, Qin L, He R, Hu C. Neutrophil extracellular trapping network promotes the pathogenesis of neutrophil-associated asthma through macrophages. Immunol Invest. 2021;50(5):544–561. doi:10.1080/08820139.2020.1778720
   PubMed Web of Science ®Google Scholar
• Dworski R, Simon HU, Hoskins A, Yousefi S. Eosinophil and neutrophil extracellular DNA traps in human allergic asthmatic airways. J Allergy Clin Immunol. 2011;127(5):1260–1266. doi:10.1016/j.jaci.2010.12.1103
   PubMed Web of Science ®Google Scholar
• Dicker AJ, Crichton ML, Pumphrey EG, et al. Neutrophil extracellular traps are associated with disease severity and microbiota diversity in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018;141(1):117–127. doi:10.1016/j.jaci.2017.04.022
   PubMed Web of Science ®Google Scholar
• Hwang CS, Park SC, Cho H-J, Park DJ, Yoon JH, Kim CH. Eosinophil extracellular trap formation is closely associated with disease severity in chronic rhinosinusitis regardless of nasal polyp status. Sci Rep. 2019;9(1):8061. doi:10.1038/s41598-019-44627-z
   PubMed Web of Science ®Google Scholar
• Lewis BW, Ford ML, Rogers LK, Britt RD Jr. Oxidative stress promotes corticosteroid insensitivity in asthma and COPD. Antioxidants. 2021;10(9):1335. doi:10.3390/antiox10091335
   Web of Science ®Google Scholar
• Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of Reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150(4):799–810. doi:10.1016/j.chest.2016.03.018
   PubMed Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366. doi:10.1016/S2213-2600(15)00042-9
   PubMed Web of Science ®Google Scholar
• Murphy K, Jacobs J, Bjermer L, et al. Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma. J Allergy Clin Immunol Pract. 2017;5(6):1572–1581.e1573. doi:10.1016/j.jaip.2017.08.024
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. doi:10.1016/S0140-6736(16)31322-8
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid–sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–2458. doi:10.1056/NEJMoa1703501
   PubMed Web of Science ®Google Scholar
• Gevaert E, Zhang N, Krysko O, et al. Extracellular eosinophilic traps in association with Staphylococcus aureus at the site of epithelial barrier defects in patients with severe airway inflammation. J Allergy Clin Immunol. 2017;139(6):1849–1860 e1846. doi:10.1016/j.jaci.2017.01.019
   PubMed Web of Science ®Google Scholar
• Bochner BS, Stevens WW. Biology and function of eosinophils in chronic rhinosinusitis with or without nasal polyps. Allergy Asthma Immunol Res. 2021;13(1):8–22. doi:10.4168/aair.2021.13.1.8
   PubMed Web of Science ®Google Scholar
• Kelsen SG, Agache IO, Soong W, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial. J Allergy Clin Immunol. 2021;148(3):790–798. doi:10.1016/j.jaci.2021.03.044
   PubMed Web of Science ®Google Scholar
• Johnston LK, Bryce PJ. Understanding interleukin 33 and its roles in eosinophil development. Front Med. 2017;4:51. doi:10.3389/fmed.2017.00051
   Web of Science ®Google Scholar
• Menzies Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800–1809. doi:10.1056/NEJMoa2034975
   PubMed Web of Science ®Google Scholar
• Gevaert E, Delemarre T, De Volder J, et al. Charcot-Leyden crystals promote neutrophilic inflammation in patients with nasal polyposis. J Allergy Clin Immunol. 2020;145(1):427–430 e424. doi:10.1016/j.jaci.2019.08.027
   PubMed Web of Science ®Google Scholar
• Allen JE, Sutherland TE. Crystal-clear treatment for allergic disease. Science. 2019;364(6442):738–739. doi:10.1126/science.aax6175
   PubMed Web of Science ®Google Scholar
• Persson EK, Verstraete K, Heyndrickx I, et al. Protein crystallization promotes type 2 immunity and is reversible by antibody treatment. Science. 2019;365(6442):eaaw4295. doi:10.1126/science.aaw4295
   Web of Science ®Google Scholar